US › Healthcare

VistaGen Therapeutics Inc (VTGN)

US · Healthcare · Biotechnology

$0.30+22.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$465,000
Revenue YoY
+3200.0%
Net profit
$-16.3M
Profit YoY
-19.4%
EPS
$-0.37
EPS estimate
$-0.42
Net margin
-3,499.8%

EPS came in at -0.37 against a street estimate of -0.42 — a beat of 11.9%.

Key statistics

Market cap
$10.1M
Forward P/E
0.0
P/B
0.28
Book value
$0.90
EPS (TTM)
$-1.83
52-week high
$5.14
52-week low
$0.20
50-day MA
$0.45
200-day MA
$1.38
Beta
0.38

Analyst view

Analysts rate VistaGen Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $1.00.

Shareholding

Insiders
0.29%
Institutions
40.89%

Largest institutional holders

FundStake
Orbimed Advisors, LLC7.46%
TCG Crossover Management, LLC6.52%
Vanguard Capital Management, LLC3.84%
StemPoint Capital LP3.01%
ADAR1 Capital Management LLC1.83%
Acadian Asset Management LLC1.44%
Ikarian Capital, LLC1.26%
Two Sigma Investments LLC1.14%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for VistaGen Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.